Susan Dexter - Sartorius Stedim Non-Executive Independent Director
| 56S1 Stock | EUR 183.30 1.10 0.60% |
Director
Ms. Susan J. Dexter was NonExecutive Independent Board Member of Sartorius Stedim Biotech SA since April 7, 2015. Previously, she was Board Member of BioSense Technologies and Chief Medical Officer of Kalon Biotherapeutics. She holds double major BS degree from American University in Washington. She attended also courses at Harvard University, Negotiation Course for Lawyers among others. since 2015.
| Age | 63 |
| Tenure | 9 years |
| Phone | 33 4 42 84 56 00 |
| Web | https://www.sartorius.com |
Susan Dexter Latest Insider Activity
Tracking and analyzing the buying and selling activities of Susan Dexter against Sartorius Stedim stock is an integral part of due diligence when investing in Sartorius Stedim. Susan Dexter insider activity provides valuable insight into whether Sartorius Stedim is net buyers or sellers over its current business cycle. Note, Sartorius Stedim insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sartorius Stedim'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Susan Dexter over six months ago Disposition of 10145 shares by Susan Dexter of Sonnet Biotherapeutics at 1.51 subject to Rule 16b-3 |
Sartorius Stedim Management Efficiency
The company has return on total asset (ROA) of 0.1548 % which means that it generated a profit of $0.1548 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4143 %, meaning that it generated $0.4143 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.41 | |||
| Return On Asset | 0.15 |
Sartorius Stedim Biotech Leadership Team
Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rene Faber, Non-Executive Director | ||
| AnneMarie Graffin, Non-Executive Independent Director | ||
| Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations | ||
| Henri Riey, Non-Executive Independent Director | ||
| Pascale Boissel, Non-Executive Independent Director | ||
| Olivier Guitard, Head BPS | ||
| Joachim Kreuzburg, Chairman of the Board and Chief Executive Officer, Chairman of the Executive Committee | ||
| Susan Dexter, Non-Executive Independent Director | ||
| Heiko Imhl, VP Relations | ||
| Amelie Buton, Non-Executive Director, Employee Representative | ||
| Lothar Kappich, Non-Executive Director | ||
| Benedikt Orzelek, Investor Relations Contact | ||
| John Mackay, Sales Marketing |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.41 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 31.28 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.81 % | |||
| Price To Earning | 110.44 X | |||
| Price To Book | 13.18 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Sartorius Stock
Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.